WEE1 and cancer: The remarkable economic success of imatinib, approved in 2001 as a small molecule inhibitor of Abelson tyrosine kinase (ABL), which is dysregulated by chromosome translocation in chronic myelogenous leukemia, kindled drug research and development targeting the protein kinases involved in other cancers and diseases [7,8,9].